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A surveillance system used different detection meth-
ods to estimate prevalence of Shiga toxin–producing
Escherichia coli during 2003–2005 and 2001–2002. More
non-O157 serotypes were detected by enzyme immunoas-
say than by evaluation of non–sorbitol-fermenting E. coli
isolates. We therefore recommend use of enzyme
immunoassay and culture-based methods.
I
nfection with Shiga toxin–producing Escherichia coli
(STEC) is a frequent cause of gastrointestinal disease,
particularly among children and elderly persons (1).
Detection of O157 STEC by culture relies primarily on
sorbitol MacConkey agar (SMAC) (2) because O157:H7
strains cannot rapidly ferment sorbitol (3). In contrast,
using culture to detect sorbitol-fermenting O157 (4) and
non-O157 serotypes is problematic because on SMAC
these strains are indistinguishable from other E. coli.
Consequently, whether the predominance of STEC O157
in disease reflects actual differences in pathogen preva-
lence or a bias associated with detection is unclear. We
therefore sought to determine whether STEC prevalence,
particularly of non-O157 serotypes, increased when
enhanced detection methods were used.
The Study
The Michigan Department of Community Health
implemented a sentinel surveillance system to evaluate
blood-containing stool samples from 20 laboratories dur-
ing April 2003–October 2005 and all stool samples from 2
hospitals during July 2004–October 2005. All suspect
non–sorbitol-fermenting E. coli from the remaining labo-
ratories were also examined.
The samples, transported in C&S transport medium
(Medical Chemical Corporation, Torrance, CA, USA),
were screened for Shiga toxin (Stx) by enzyme immunoas-
say (EIA) (Meridian BioScience, Cincinnati, OH, USA)
after enrichment with gram-negative broth (Remel,
Lenexa, KS, USA). EIA is sensitive and specific but can-
not detect the Stx2e variant (5), and Pseudomonas aerugi-
nosa can produce false-positive results (6). Samples were
cultured on SMAC (Remel) and cefixime-tellurite SMAC
(7), and samples from the 2 hospitals were tested for occult
blood (Beckman Coulter, Fullerton, CA, USA) before EIA
testing. Serotyping (Statens Serum Institute, Copenhagen,
Denmark; BD Difco, Franklin Lakes, NJ, USA) and real-
time PCR for stx1,2 genes (8) were performed on strains
that had positive EIA results, suspect non–sorbitol-fer-
menting E. coli, and multiple colonies of sorbitol-ferment-
ing (SF) strains that had positive EIA results. For some
samples, the EIA result was negative but NSF stx-positive
colonies were detected on SMAC, which indicated a false-
negative EIA result. Epidemiologic data were obtained for
STEC-positive patients.
During the 5 years studied, 438 STEC were isolated;
401 (92%) were O157. Prevalence over time did not differ
(χ2  = 4.14, degrees of freedom [df] = 4, p = 0.39).
Similarly, overall prevalence of non-O157 serotypes dur-
ing 2001–2002 and 2003–2005 did not differ (χ2 = 0.83, df
= 1, p = 0.36). Most (70%) STEC isolates were recovered
between June and October from heavily populated areas
(Figure). No SF O157 were recovered.
In 2001–2002, a total of 664 suspect NSF E. coli iso-
lates were evaluated; 179 (27%) were O157 and 2 (0.3%)
were non-O157 serotypes (Table 1). After enhanced sur-
veillance began in 2003, a total of 852 suspect isolates
were tested; 177 (21%) were O157 and 3 (0.4%) were non-
O157 serotypes (Table 1). The remaining STEC (n = 28,
2001–2002; n = 49, 2003–2005) were detected by EIA. For
5 samples, EIA yielded a false-negative result but STEC
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Figure. Frequency of isolation of Shiga toxin–producing
Escherichia coli (STEC), Michigan, 2001–2005. Enhanced surveil-
lance for STEC began in April 2003.were recovered from SMAC. During 2003–2005, 7 of the
49 STEC came from screening all 2,426 samples from the
2 hospitals; 359 (15%) of these samples contained occult
blood. Among the 7 detected, 5 contained occult blood and
6 were O157. The remaining 42 (10%) STEC were found
by screening 423 suspect samples from other laboratories;
18 (4%) were non-O157 serotypes. More non-O157
serotypes were detected (χ2 = 61.1, df = 1, p<0.00001)
from 2003–2005 when EIAwas used instead of the NSF E.
coli isolate submission process. Among all 37 non-O157
serotypes isolated, O45:H2 (n = 10) and O26:H11 (n = 5)
predominated.
Epidemiologic data were available for up to 389
(89%) STEC patients, depending on the variable assessed.
Most patients (62%) were Caucasian; ≈50% were female.
Disease occurred mostly in persons <10 (27%), 11–18
(19%), and 19–30 (17%) years of age. Although disease
frequency was lower (9%) in persons >65 years of age,
these persons were more likely to be hospitalized than
were persons <18 years of age, as were persons with
bloody diarrhea or hemolytic-uremic syndrome (HUS)
(Table 2). Among the 12 patients with HUS, 2 were infect-
ed with non-O157 serotypes O103:H2 and O76:H7, and 7
of the 12 HUS-associated strains were stx2 only.
To adjust for factors associated with hospitalization,
we fit a logistic regression model that included age and
symptom variables in the model. The adjusted associations
were similar to the crude associations. Hospitalization was
more frequent for persons with bloody diarrhea (adjusted
odds ratio [OR] 1.8, 95% confidence interval [CI]
1.04–3.08) and HUS (adjusted OR 16.0, 95% CI
2.00–127.47). Also, persons 19–64 (adjusted OR 1.6, 95%
CI 1.05–2.59) and >65 (adjusted OR 6.6, 95% CI
2.57–17.15) years of age were hospitalized more frequent-
ly than persons ≤18 years of age. 
Conclusions
Enhanced detection methods did not significantly
increase the year-to-year recovery of STEC. Overall, the
observed STEC prevalence decreased slightly over time,
similar to the national trend of an overall 42% decrease in
STEC O157 incidence during 1996–2004 (9). This reduc-
tion is likely attributable to numerous factors, including
heightened consumer awareness (9) and improved screen-
ing protocols during food production (10).
Enhanced surveillance did, however, enhance detec-
tion of non-O157 serotypes; 4.3% of EIA-positive stools
were non-O157 compared with 0.5% of suspect NSF E.
coli. Additionally, among the STEC found, 34 (48%) were
non-O157 and 37 (52%) were O157 when EIA was used
on suspect stools, compared with only 3 (1.6%) non-O157
and 177 (98.3%) O157 among NSF E. coli. Despite
enhanced surveillance, STEC prevalence is probably still
underestimated, particularly for non-O157 serotypes,
because not all ill persons seek medical care and not all
laboratories submit suspect stools for evaluation.
Nevertheless, in 5 years, our surveillance identified 66
(15%) cases that would have been undetected by conven-
tional methods; 31 (47%) were non-O157. Among those
patients for whom data were available, 27 (42%) of 64
were <18 years of age, 22 (43%) of 51 were hospitalized,
and 39 (76%) of 51 had bloody diarrhea. Although bloody
stool and patient age are poor predictors of STEC infection
(11), our analysis demonstrates that screening bloody stool
samples improves detection of non-O157, and blood and
older age are important predictors of more severe disease,
which may be more costly if undetected. 
Hospitalization of STEC patients with and without
HUS costs an estimated US $30,307 and $4,061 per
patient, respectively (12). Therefore, Michigan hospital
costs associated with STEC infection likely exceeded
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talized and 12 had HUS. Identification of each additional
STEC case could have a substantial public health effect in
that 1 case may lead to the recognition of an outbreak,
which if detected early, could contribute to a cost savings
as well as reduced STEC-associated illness. We estimated
that the cost to detect each of the 66 additional cases using
the EIA ($7 per test including labor) differed considerably
when we evaluated screening of all stool samples
($2,426/per positive) versus suspect stool samples
($10/per positive).
No widely available test detects all STEC, and use of
multiple methods is not cost-effective. Consequently, we
recommend using EIA in conjunction with SMAC culture
to recover isolates for molecular characterization and sub-
sequent outbreak investigations. Although occult blood
tests did not enhance the sensitivity of STEC recovery,
patient data and accompanying epidemiologic information
may help identify which samples to test, thereby prevent-
ing future outbreaks. Because such epidemiologic infor-
mation is often not available to laboratory personnel, we
suggest that clinical laboratories work with medical
administrations to use EIAs as their standard of practice
and to facilitate routine availability of such information.
Until more sensitive and cost-effective STEC screening
methods are available, facilities that cannot implement
EIAs should forward stool samples that are suspect, as
well as those with positive screening results, to public
health laboratories. These laboratories can easily evaluate
suspect stools for STEC by EIA or PCR followed by cul-
ture of all positive samples to recover the isolate for further
characterization.
Acknowledgments
We thank Francis Pouch Downes, Carrie Anglewicz,
Barbara Evans, Kendra Anspaugh, Kelly Scott, Hao Trinh, Ben
Hutton, Jon George, John Dyke, Kevin Rodeman, Jeff Massey,
Steve Tharpe, Mary Grace Stobierski, Jim Collins, Michael Hass,
DISPATCHES
320 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 2, February 2007Sally Bidol, Theresa Painter, James Wolcott, Eileen Matthews,
Janet Green, Dave Aldrich, Carl Pierson, Duane Newton, Cora
Manby, Richard Van Enk, Alan Petkus, Joan Baughman, Linda
Hayka, Vito Damore, Cindy Miilu, Sharon Gauthier, John Kuehn,
Marie Graham, Therese Carson, and Daniel Sundin. 
The Emerging Infectious Diseases Research Fellowship
Program, administered by the Association of Public Health
Laboratories and funded by the US Centers for Disease Control
and Prevention (CDC), supported S. Manning’s appointment
(2002–2004), and the CDC/Council of State and Territorial
Epidemiologists Applied Epidemiology Fellowship Program sup-
ported R. Madera’s appointment (2003–2005). This project was
supported in part with federal funds for the Food and Waterborne
Disease Integrated Research Network under National Institutes
of Health research contract no. N01-AI-30058.
Dr Manning is a molecular and infectious disease epidemi-
ologist. She studies the molecular epidemiology of pathogenic
E. coli and group B Streptococcus at Michigan State University.
References
1.  Thorpe CM. Shiga toxin–producing Escherichia coli infection. Clin
Infect Dis. 2004;38:1298–303.
2.  March SB, Ratnam S. Sorbitol-MacConkey medium for detection
of Escherichia coli O157:H7 associated with hemorrhagic colitis. J
Clin Microbiol. 1986;23:869–72.
3.  Farmer JJ, Davis BR. H7 antiserum-sorbitol fermentation medium:
a single tube screening medium for detecting Escherichia coli
O157:H7 associated with hemorrhagic colitis. J Clin Microbiol.
1985;22:620–5.
4.  Karch H, Bielaszewska M. Sorbitol-fermenting Shiga toxin-produc-
ing Escherichia coli O157:H(-) strains: epidemiology, phenotypic
and molecular characteristics, and microbiological diagnosis. J Clin
Microbiol. 2001;39:2043–9.
5.  Allerberger F, Rossboth D, Dierich MP, Aleksic S, Schmidt H,
Karch H. Prevalence and clinical manifestations of Shiga
toxin–producing Escherichia coli infections in Austrian children.
Eur J Clin Microbiol Infect Dis. 1996;15:545–50.
6.  Beutin L, Zimmermann S, Gleier K. Pseudomonas aeruginosa can
cause false-positive identification of verotoxin (Shiga-like toxin)
production by a commercial enzyme immune assay system for the
detection of Shiga-like toxins (SLTs). Infection. 1996;24:267–8.
7.  Zadik PM, Chapman PA, Siddons CA. Use of tellurite for the selec-
tion of verocytotoxigenic Escherichia coli O157. J Med Microbiol.
1993;39:155–8.
8.  Reischl U, Youssef MT, Kilwinski J, Lehn N, Zhang WL, Karch H,
et al. Real-time fluorescence PCR assays for detection and charac-
terization of Shiga toxin, intimin, and enterohemolysin genes from
Shiga toxin–producing Escherichia coli. J Clin Microbiol.
2002;40:2555-65.
9.  Centers for Disease Control and Prevention. Preliminary FoodNet
data on the incidence of infection with pathogens transmitted com-
monly through food-10 sites, United States, 2004. MMWR Morb
Mortal Wkly Rep. 2005;54:352–6.
10.  Naugle AL, Holt KG, Levine P, Eckel R. Food safety and inspection
service regulatory testing program for Escherichia coli O157:H7 in
raw ground beef. J Food Prot. 2005;68:462–8.
11.  Kehl KS, Havens P, Behnke CE, Acheson DW. Evaluation of the
premier EHEC assay for detection of Shiga toxin–producing
Escherichia coli. J Clin Microbiol. 1997;35:2051–4.
12.  Frenzen PD, Drake A, Angulo FJ. Economic cost of illness due to
Escherichia coli O157 infections in the United States. J Food Prot.
2005;68:2623–30.
Address for correspondence: James T. Rudrik, Michigan Department of
Community Health, Bureau of Laboratories, 3350 North Martin Luther
King Jr Blvd, Bldg 44, Rm 129, Lansing, MI 48909, USA; email:
RudrikJ@michigan.gov
Surveillance for STEC, Michigan
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 2, February 2007 321
Use of trade names is for identification only and does not imply
endorsement by the Public Health Service or by the U.S.
Department of Health and Human Services.
The Public Health Image Library (PHIL), Centers for Disease Control and
Prevention, contains thousands of public health-related images, including 
high-resolution (print quality) photographs, illustrations, and videos. 
PHIL collections illustrate current events and articles, supply visual content for
health promotion brochures, document the effects of disease, and enhance
instructional media.
PHIL Images, accessible to PC and Macintosh users, are in the public domain
and available without charge. 
Visit PHIL at http://phil.cdc.gov/phil.
The Public Health Image Library (PHIL)
Search past issues of EID at www.cdc.gov/eid